(6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-pyridin-3-ylmethyl-amine | 1174631-09-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: (6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-pyridin-3-ylmethyl-amine
• 英文别名: 6-chloro-1-methyl-N-(pyridin-3-ylmethyl)pyrazolo[3,4-d]pyrimidin-4-amine
• CAS: 1174631-09-4
• 化学式: C₁₂H₁₁ClN₆
• 分子量: 274.713
• InChiKey: FSBVOSRLHTVVGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  68.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-氨甲基吡啶 、 4,6-二氯-1-甲基-1H-吡唑并[3,4-d]嘧啶 以gave (6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-pyridin-3-ylmethyl-amine的产率得到(6-chloro-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-pyridin-3-ylmethyl-amine
  参考文献：
  名称：

  PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE

  摘要：

  具有I式化合物的立体异构体、几何异构体、互变异构体、溶剂化物、代谢物和药物可接受的盐，对于抑制脂质激酶包括p110α和其他PI3K同工酶以及治疗由脂质激酶介导的癌症等疾病是有用的。公开了使用I式化合物的方法，用于哺乳动物细胞中的体外、原位和体内诊断、预防或治疗这种疾病，或相关的病理条件。

  公开号：

  US20110172216A1

文献信息

• [EN] PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS DE PYRAZOLOPYRIMIDINE INHIBANT PI3K ET PROCÉDÉS D'UTILISATION
  申请人：GENENTECH INC

  公开号：WO2009097446A1

  公开（公告）日：2009-08-06

  Compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. [Fomula I]

  式I的化合物，包括立体异构体、几何异构体、互变异构体、溶剂合物、代谢物和其药用可接受的盐，用于抑制脂质激酶，包括p110α和PI3K的其他同工酶，并用于治疗由脂质激酶介导的癌症等疾病。公开了使用式I的化合物进行体外、体内和体内诊断、预防或治疗哺乳动物细胞中的这类疾病或相关病理条件的方法。【式I】
• PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Dotson Jennafer

  公开号：US20110172216A1

  公开（公告）日：2011-07-14

  Compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  具有I式化合物的立体异构体、几何异构体、互变异构体、溶剂化物、代谢物和药物可接受的盐，对于抑制脂质激酶包括p110α和其他PI3K同工酶以及治疗由脂质激酶介导的癌症等疾病是有用的。公开了使用I式化合物的方法，用于哺乳动物细胞中的体外、原位和体内诊断、预防或治疗这种疾病，或相关的病理条件。
• US8987280B2
  申请人：——

  公开号：US8987280B2

  公开（公告）日：2015-03-24
• Pyrazolopyrimidine PI3K inhibitor compounds and methods of use
  申请人：Dotson Jennafer

  公开号：US08987280B2

  公开（公告）日：2015-03-24

  Compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  式I的化合物，包括立体异构体、几何异构体、互变异构体、溶剂化物、代谢物和药学上可接受的盐，对于抑制脂质激酶包括p110 alpha和PI3K的其他同系物，并用于治疗由脂质激酶介导的癌症等疾病具有用处。揭示了使用式I的化合物进行哺乳动物细胞中的体外、体内和原位诊断、预防或治疗此类疾病或相关病理条件的方法。